Q-omics provides the consensus-scored RPL36AP45 profile across patient tissues and cancer cell-line models. RPL36AP45 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL36AP45 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, RPL36AP45 RNA expression shows 7,830 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, THCA, and ACC as cancer lineages where RPL36AP45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP45 survival associations across molecular data types. RPL36AP45 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP45 RNA expression–survival associations across cancer types. High RPL36AP45 expression shows unfavorable associations in LIHC and READ, but favorable associations in CESC, UVM, COAD and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL36AP45 RNA expression.
This table summarizes RPL36AP45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP45 shows lower tumor expression in THCA and BRCA and higher tumor expression in LUSC, CHOL and LUAD. The THCA box plot shows higher RPL36AP45 RNA expression in normal versus tumor tissue (log2 FC = −1.287, t-test p < 0.001).
This table shows molecular features associated with RPL36AP45 in patient tissues and cancer cell lines. In patient samples, RPL36AP45 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
